Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02168127 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
A Phase 3 study, sponsored by Rhodes Pharmaceuticals, L.P..
- Completed
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
NCT02168127 is a Phase 3 study that has completed, run by Rhodes Pharmaceuticals, L.P.. The registered enrollment target is 360 participants.
The verdict
NCT02168127, a Phase 3 study, has completed, sponsored by Rhodes Pharmaceuticals, L.P..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
Study Summary
The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.
Interventions
- DRUG Drug: PRC-063
- DRUG PRC-063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02168127
The ClinicalTrials.gov registry entry for NCT02168127 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhodes Pharmaceuticals, L.P., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Drug: PRC-063 is the first listed.
NCT02168127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02168127 about?
NCT02168127 is a clinical study titled "Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD". The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.
What is the current status of trial NCT02168127?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2014-05. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02168127?
The interventions under investigation include: Drug: PRC-063 (DRUG), PRC-063 (DRUG).
Who is sponsoring clinical trial NCT02168127?
This trial is sponsored by Rhodes Pharmaceuticals, L.P., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.